In the sections that follow, we critically examine the emerging roles of RKIP and YY1 in the context of metabolic disease, highlight current knowledge gaps, and discuss potential therapeutic implications for obesity, T2D, and cardiovascular disorders. This evidence concerns the gene PEBP1 and obesity due to melanocortin 4 receptor deficiency.